208 results on '"Holle, Julia U."'
Search Results
2. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
3. Eosinophilie: hypereosinophiles Syndrom versus eosinophile Granulomatose mit Polyangiitis
4. ANCA-assoziierte Vaskulitis
5. Therapie-Update der ANCA-assoziierten Vaskulitiden: Granulomatose mit Polyangiitis und Mikroskopische Polyangiitis
6. Gelenkschmerzen – eine rheumatische Erkrankung?
7. German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis
8. Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Management der Glukokortikoid-induzierten Osteoporose
9. Kortisonfreie Rheumatologie – Vaskulitiden
10. Gelenkschmerzen – eine rheumatische Erkrankung?
11. Erratum zu: Empfehlungen der Deutschen Gesellschaft für Rheumatologie zum Management der Glukokortikoid-induzierten Osteoporose
12. Drei Jahre Terminservicestelle: hohe Rate an Fehlzuweisungen und No-show-Patienten – Eine retrospektive Auswertung des Rheumazentrum Schleswig-Holstein Mitte
13. EULAR recommendations for the management of ANCA- associated vasculitis: 2022 update.
14. Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis
15. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
16. S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden
17. Die neue Rubrik „So behandle ich …“
18. Wegener Granulomatosis
19. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort
20. ANCA-assoziierte Vaskulitiden
21. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim–Chester disease refractory to anakinra: successful use of vemurafenib
22. Of evidence and uncertainties
23. Granulomatosis with Polyangiitis (Wegener’s Granulomatosis)
24. ANCA-assoziierte Vaskulitiden: Granulomatose mit Polyangiitis (GPA, Morbus Wegener) und mikroskopische Polyangiitis
25. Twenty-eight years with antineutrophil cytoplasmic antibodies (ANCA): how to test for ANCA — evidence-based immunology?
26. A functionally relevant IRF5 haplotype is associated with reduced risk to Wegener’s granulomatosis
27. The SEM6A6 Locus Is Not Associated With Granulomatosis With Polyangiitis or Other Forms of Antineutrophil Cytoplasmic Antibody–Associated Vasculitides in Europeans: Comment on the Article by Xie et al
28. Clinical features of ANCA-associated vasculitis
29. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
30. Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis
31. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage
32. Genetically Distinct Subsets within ANCA-Associated Vasculitis
33. Rituximab for refractory granulomatosis with polyangiitis (Wegenerʼs granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations
34. VASCULITIS SYNDROMES: Rituximab in AAV: when and how to use it
35. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma
36. Improved outcome in 445 patients with Wegenerʼs granulomatosis in a German vasculitis center over four decades
37. Prospective long-term follow-up of patients with localised Wegenerʼs granulomatosis: does it occur as persistent disease stage?
38. Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener’s granulomatosis and Churg–Strauss syndrome
39. Diagnostic and therapeutic management of Churg–Strauss syndrome
40. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
41. Update Therapie der ANCA-assoziierten Vaskulitiden
42. Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis
43. Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis
44. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Cent
45. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort
46. TheSEM6A6Locus Is Not Associated With Granulomatosis With Polyangiitis or Other Forms of Antineutrophil Cytoplasmic Antibody-Associated Vasculitides in Europeans: Comment on the Article by Xie et al
47. Genetically Distinct Subsets within ANCA-Associated Vasculitis
48. Caveolin-1 Single Nucleotide Polymorphism in Antineutrophil Cytoplasmic Antibody Associated Vasculitis
49. L43. Seropositive and negative ANCA-associated vasculitis, anti-MPO and PR3-vasculitis: Different outcomes?
50. Treatment of ANCA-associated vasculitides (AAV)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.